Male partner age, viral load, and HIV infection in adolescent girls and young women: Evidence from eight sub-Saharan African countries

Sep 26, 2022

Abstract: Objective: We aimed to elucidate the role of partnerships with older men in the HIV epidemic among adolescent girls and young women (AGYW) aged 15–24 years in sub-Saharan Africa. Design: Analysis of Population-based HIV Impact Assessments (PHIAs) in...

March 2021: Expanded, population-level access to PrEP through the SEARCH study, with a flexible service delivery model, associated with lower HIV incidence among PrEP initiators in rural communities in Kenya and Uganda

Mar 30, 2021

Article: HIV incidence after pre-exposure prophylaxis initiation among women and men at elevated HIV risk: A population-based study in rural Kenya and Uganda. Published in: PLoS Med. 2021;18(2):e1003492 https://doi.org/10.1371/journal.pmed.1003492 Authors: Koss CA,...

HIV incidence by male circumcision status from the population-based HIV impact assessment (PHIA) surveys-eight sub-Saharan African countries, 2015-2017

Mar 26, 2021

Hines JZ, Sachathep K, Pals S, Davis SM, Toledo C, Bronson M, Parekh B, Carrasco M, Xaba S, Mandisarisa J, Kamobyi R, Chituwo O, Kirungi WL, Alamo S, Kabuye G, Awor AC, Mmbando S, Simbeye D, Aupokolo MA, Zemburuka B, Nyirenda R, Msungama W, Tarumbiswa T, Manda R,...

February 2021: Safety, uptake, and use of a dapivirine vaginal ring for HIV-1 prevention in African women (HOPE): an open-label, extension study

Feb 23, 2021

Article: Safety, uptake, and use of a dapivirine vaginal ring for HIV-1 prevention in African women (HOPE): an open-label, extension study Published in: Lancet HIV. 2021;8(2):e87-e95 https://doi.org/10.1016/S2352-3018(20)30304-0 Authors: Baeten JM, Palanee-Phillips T,...

January 2021: Long-acting cabotegravir and rilpivirine dosed every 2 months in adults with HIV-1 infection (ATLAS-2M), 48-week results

Feb 1, 2021

Article and Study Summary Long-acting cabotegravir and rilpivirine dosed every 2 months in adults with HIV-1 infection (ATLAS-2M), 48-week results: a randomised, multicentre, open-label, phase 3b, non-inferiority study Published in: Lancet. 2020;396 (10267):1994-2005...

Viral Load